Novo Nordisk will sell its long-acting insulin Tresiba (degludec) in Europe at a 60-70 percent premium over rival product Lantus from France’s Sanofi.

Novo is in the process of negotiating prices of the new insulin in Europe, and recently agreed with authorities in the United Kingdom to price the insulin 60-70 percent above competing products in the market, as it is believed to hold some advantages over its rivals.

As the world suffers from an epidemic of type 2 diabetes tied to over-eating and lack of exercise, demand for treatments has snowballed and competition intensified.
Earlier this week, the U.S. Food and Drug Administration (FDA) refused to approve Novo’s Tresiba until it conducts extra tests for potential heart risks, dealing a major blow to a key product for the Danish drugmaker.

Tresiba has already been approved in Europe and Japan.

Sanofi’s Lantus is expected to continue its double-digit sales growth after the FDA refused to approve Tresiba.
The French company said on Wednesday it would invest 44 million euros ($59 million) on its site in Waterford, Ireland, to boost production of Lantus.

Novo Nordisk has said it expects to launch Tresiba in the UK and Denmark in the first half of 2013, and in other European countries later this year and next year.

Reuters Health

Nyhetsinfo
www red DiabetologNytt